Analyst Price Target is $15.75
▲ +316.67% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for TRACON Pharmaceuticals in the last 3 months. The average price target is $15.75, with a high forecast of $24.00 and a low forecast of $12.00. The average price target represents a 316.67% upside from the last price of $3.78.
Current Consensus is
The current consensus among 5 contributing investment analysts is to buy stock in TRACON Pharmaceuticals. This Buy consensus rating has held steady for over two years.
TRACON Pharmaceuticals, Inc. engages in the development and commercialization of targeted therapies for cancer, ophthalmic, and fibrotic diseases. Its products include TRC105, an anti-endoglin antibody for the treatment of solid tumor types; TRC205 created for the treatment of fibrotic diseases; and TRC102, a small molecule that is in clinical development made for lung cancer and glioblastoma. The company was founded in October 2004 and is headquartered in San Diego, CA.